Literature DB >> 19699154

Long-term vagus nerve stimulation in the treatment of Lennox-Gastaut syndrome.

Konstantin Kostov1, Hrisimir Kostov, Erik Taubøll.   

Abstract

The long-term effects of vagus nerve stimulation (VNS) on seizure frequency were studied in 30 patients with Lennox-Gastaut syndrome. Median observation time was 52 months (17-123). The effect parameters investigated were total number of seizures and different seizure types. The median reduction in number of seizures was 60.6%. The effects of VNS varied considerably between seizure types. Best effects were observed with atonic seizures (80.8% median reduction, number of responders: 8/12), followed closely by tonic seizures (73.3% median reduction, number of responders: 8/13). Least effects were with generalized tonic-clonic seizures (median reduction 57.4%, number of responders: 11/20). Additional positive effects included milder or shorter ictal or postictal phase in 16 patients. Improved alertness was reported in 76.7%. Adverse effects, of which drooling and voice alteration were most frequent, were reported in 20 patients. There was a statistically significant reduction in the median number of antiepileptic drugs used. The discontinuation rate was 16.7%.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19699154     DOI: 10.1016/j.yebeh.2009.07.038

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  13 in total

Review 1.  Seizure detection: do current devices work? And when can they be useful?

Authors:  Xiuhe Zhao; Samden D Lhatoo
Journal:  Curr Neurol Neurosci Rep       Date:  2018-05-23       Impact factor: 5.081

2.  Neurostimulation-past, present, and beyond.

Authors:  Elinor Ben-Menachem
Journal:  Epilepsy Curr       Date:  2012-09       Impact factor: 7.500

Review 3.  Minimally invasive surgical approaches for temporal lobe epilepsy.

Authors:  Edward F Chang; Dario J Englot; Sumeet Vadera
Journal:  Epilepsy Behav       Date:  2015-05-24       Impact factor: 2.937

Review 4.  Comparison and Selection of Current Implantable Anti-Epileptic Devices.

Authors:  Stephen Wong; Ram Mani; Shabbar Danish
Journal:  Neurotherapeutics       Date:  2019-04       Impact factor: 7.620

Review 5.  Vagus nerve stimulation vs. corpus callosotomy in the treatment of Lennox-Gastaut syndrome: a meta-analysis.

Authors:  Guido Lancman; Michael Virk; Huibo Shao; Madhu Mazumdar; Jeffrey P Greenfield; Steven Weinstein; Theodore H Schwartz
Journal:  Seizure       Date:  2012-10-12       Impact factor: 3.184

Review 6.  Toward rational design of electrical stimulation strategies for epilepsy control.

Authors:  Sridhar Sunderam; Bruce Gluckman; Davide Reato; Marom Bikson
Journal:  Epilepsy Behav       Date:  2009-11-17       Impact factor: 2.937

Review 7.  Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: report of the Guideline Development Subcommittee of the American Academy of Neurology.

Authors:  George L Morris; David Gloss; Jeffrey Buchhalter; Kenneth J Mack; Katherine Nickels; Cynthia Harden
Journal:  Neurology       Date:  2013-08-28       Impact factor: 9.910

8.  Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: report of the guideline development subcommittee of the american academy of neurology.

Authors:  George L Morris; David Gloss; Jeffrey Buchhalter; Kenneth J Mack; Katherine Nickels; Cynthia Harden
Journal:  Epilepsy Curr       Date:  2013-11       Impact factor: 7.500

Review 9.  Corpus callosotomy versus vagus nerve stimulation for atonic seizures and drop attacks: A systematic review.

Authors:  John D Rolston; Dario J Englot; Doris D Wang; Paul A Garcia; Edward F Chang
Journal:  Epilepsy Behav       Date:  2015-08-03       Impact factor: 2.937

10.  Novel Neurotechnological Interventions for Pediatric Drug-Resistant Epilepsy: Physician Perspectives.

Authors:  Patrick J McDonald; Viorica Hrincu; Mary B Connolly; Mark J Harrison; George M Ibrahim; Robert P Naftel; Winston Chiong; Farhad Udwadia; Judy Illes
Journal:  J Child Neurol       Date:  2020-10-28       Impact factor: 1.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.